StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences cash

Cash and short-term investments held at the end of each period.

Evofem Biosciences's cash was $285.00K at Jun 30, 2026. For fiscal 2025 it was $578.00K, down 22.0% from the year before. Over ten years it grew -34.2% a year on average. The highest annual figure on record is $75.95M in fiscal 2014.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$578.00K-22.0%
FY2024Dec 31, 2024$741.00K+27.8%
FY2023Dec 31, 2023$580.00K-87.9%
FY2022Dec 31, 2022$4.78M-64.9%
FY2021Dec 31, 2021$13.59M-81.2%
FY2020Dec 31, 2020$72.25M+334.6%
FY2019Dec 31, 2019$16.63M+844.1%
FY2018Dec 31, 2018$1.76M+3.5%
FY2017Dec 31, 2017$1.70M-85.2%
FY2016Dec 31, 2016$11.48M-69.6%
FY2015Dec 31, 2015$37.75M-50.3%
FY2014Dec 31, 2014$75.95M+1640.3%
FY2013Dec 31, 2013$4.36M-60.7%
FY2012Dec 31, 2012$11.10M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$285.00K-61.9%
Q1 FY2026Mar 31, 2026$1.49M+34.4%
Q4 FY2025Dec 31, 2025$578.00K-22.0%
Q3 FY2025Sep 30, 2025$840.00K+16.3%
Q2 FY2025Jun 30, 2025$748.00K+8.1%
Q1 FY2025Mar 31, 2025$1.11M+61.0%
Q4 FY2024Dec 31, 2024$741.00K+27.8%
Q3 FY2024Sep 30, 2024$722.00K+13.5%
Q2 FY2024Jun 30, 2024$692.00K+8.3%
Q1 FY2024Mar 31, 2024$689.00K-85.6%
Q4 FY2023Dec 31, 2023$580.00K-92.5%
Q2 FY2023Jun 30, 2023$636.00K-96.8%
Q1 FY2023Mar 31, 2023$639.00K-77.2%
Q4 FY2022Dec 31, 2022$4.78M-64.9%
Q3 FY2022Sep 30, 2022$7.75M-48.0%
Q2 FY2022Jun 30, 2022$19.89M-57.7%
Q1 FY2022Mar 31, 2022$2.80M-93.8%
Q4 FY2021Dec 31, 2021$13.59M-81.2%
Q3 FY2021Sep 30, 2021$14.90M-82.8%
Q2 FY2021Jun 30, 2021$47.00M-62.0%
Q1 FY2021Mar 31, 2021$45.30M+339.8%
Q4 FY2020Dec 31, 2020$72.25M+334.6%
Q3 FY2020Sep 30, 2020$86.70M+169.9%
Q2 FY2020Jun 30, 2020$123.60M+143.9%
Q1 FY2020Mar 31, 2020$10.30M+5497.8%
Q4 FY2019Dec 31, 2019$16.63M+844.1%
Q3 FY2019Sep 30, 2019$32.12M+166.0%
Q2 FY2019Jun 30, 2019$50.68M+122.4%
Q1 FY2019Mar 31, 2019$184.00K-96.3%
Q4 FY2018Dec 31, 2018$1.76M+3.5%
Q3 FY2018Sep 30, 2018$12.08M+229.9%
Q2 FY2018Jun 30, 2018$22.79M+2118.9%
Q1 FY2018Mar 31, 2018$5.03M+10.5%
Q4 FY2017Dec 31, 2017$1.70M-85.2%
Q3 FY2017Sep 30, 2017$3.66M-74.5%
Q2 FY2017Jun 30, 2017$1.03M-95.2%
Q1 FY2017Mar 31, 2017$4.55M–
Q4 FY2016Dec 31, 2016$11.48M–
Q3 FY2016Sep 30, 2016$14.36M–
Q2 FY2016Jun 30, 2016$21.47M–

More Evofem Biosciences figures

See a number that looks wrong?